Dan Forche
President & CEO of PreludeDx
| 0:00 | Speaker Introductions & Agenda |
Fredrik Warnberg, MD, PhD
Professor in the Dept. of Surgery, University of Gothenburg, Sweden
| 2:09 | Rationale for DCISionRT Validation in SweDCIS |
Troy Bremer, PhD
Founder & Chief Scientific Officer of PreludeDx
| 4:39 | Summary of DCISionRT Randomized SweDCIS Results |
Pat Whitworth, MD, FACS
Breast Surgical Oncology Specialist, Director of the Nashville Breast Center
| 9:33 | Clinical Value beyond Clinpath |
| 9:33 | Decision Impact/Clinical Utility Study Results |
| 15:15 | Surgical Perspective on the Clinical Impact of DCISionRT |
Chirag Shah, MD
Co-Director of the Comprehensive Breast Program, Cleveland Clinic
| 16:32 | Consistent Prediction of RT Benefit |
| 16:32 | DCISionRT Risk Stratifies RTOG |
| 20:42 | Clinical Implications of DCISionRT for Radiation Oncologists |
Case Studies
| 22:00 | Case Studies |
Panel Discussion with the Speakers
| 39:19 | Standard of Care in Sweden – Fredrik Warnberg, MD, PhD |
| 40:18 | Ordering DCISionRT on a Pre-Surgical Biopsy – Pat Whitworth, MD, FACS |
| 44:11 | The Future of DCISionRT – Troy Bremer, PhD |
| 47:00 | Use of Tamoxifen in Patients with DCIS – Bruce Mann, MBBS, PhD, FRACS. Chirag Shah, MD. Frank Vicini, MD, FACR, FASTRO, FABS. Pat Whitworth, MD, FACS. |
| 50:46 | Surgical Margins – Chirag Shah, MD & Pat Whitwoth, MD, FACS |
Q and A with the Panelists
| 53:27 | Are patients with higher residual risk candidates for mastectomy? |
| 55:40 | How is DCISionRT validated for margin status? |
| 56:04 | Is DCISionRT the “gold standard” of care for DCIS? |
| 57:38 | Biologic Drivers in DCISionRT |
| 1:00:52 | What do DCISionRT’s independent studies look like when combined? |
| 1:02:28 | Confidence when using clinicopathology factors to make decisions |
Closing Remarks
| 1:04:00 | Closing Remarks from Troy Bremer |